BioXcel Therapeutics' stock surged nearly 20% pre-market after reporting positive Phase 2 results for its opioid withdrawal drug, BXCL1. The 80-patient study showed a 30% reduction in withdrawal symptoms, suggesting it could rival standard treatments like loxapine. The results suggest the drug offers strong efficacy without the sedation side effects, positioning it as a superior alternative.